222 related articles for article (PubMed ID: 35716118)
1. A new exploration toward adamantane derivatives as potential anti-MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors.
Ragab A; Abusaif MS; Aboul-Magd DS; Wassel MMS; Elhagali GAM; Ammar YA
Drug Dev Res; 2022 Sep; 83(6):1305-1330. PubMed ID: 35716118
[TBL] [Abstract][Full Text] [Related]
2. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study.
Ammar YA; Micky JA; Aboul-Magd DS; Abd El-Hafez SMA; Hessein SA; Ali AM; Ragab A
Chem Biol Drug Des; 2023 Feb; 101(2):245-270. PubMed ID: 36305722
[TBL] [Abstract][Full Text] [Related]
3. New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus.
Samir M; Ramadan M; Abdelrahman MH; Elbastawesy MAI; Halby HM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Med Chem; 2022 Nov; 73():117004. PubMed ID: 36148773
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular modeling, and antimicrobial potential of novel 3-[(1H-pyrazol-3-yl)imino]indolin-2-one derivatives as DNA gyrase inhibitors.
Alzahrani AY; Ammar YA; Salem MA; Abu-Elghait M; Ragab A
Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100266. PubMed ID: 34747519
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
7. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
[TBL] [Abstract][Full Text] [Related]
8. Structure based design and synthesis of 3-(7-nitro-3-oxo-3,4-dihydroquinoxalin-2-yl)propanehydrazide derivatives as novel bacterial DNA-gyrase inhibitors: In-vitro, In-vivo, In-silico and SAR studies.
Saleh MA; Elmaaty AA; El Saeed HS; Saleh MM; Salah M; Ezz Eldin RR
Bioorg Chem; 2022 Dec; 129():106186. PubMed ID: 36215786
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.
Omar MA; Masaret GS; Abbas EMH; Abdel-Aziz MM; Harras MF; Farghaly TA
Bioorg Chem; 2020 Nov; 104():104316. PubMed ID: 33022549
[TBL] [Abstract][Full Text] [Related]
10. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives.
El-Shershaby MH; El-Gamal KM; Bayoumi AH; El-Adl K; Ahmed HEA; Abulkhair HS
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000277. PubMed ID: 33078877
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors.
Mohammed HHH; Ali DME; Badr M; Habib AGK; Mahmoud AM; Farhan SM; Gany SSHAE; Mohamad SA; Hayallah AM; Abbas SH; Abuo-Rahma GEA
Mol Divers; 2023 Aug; 27(4):1751-1765. PubMed ID: 36152132
[TBL] [Abstract][Full Text] [Related]
15. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 1H-tetrazol-5-amine based potent antimicrobial agents: DNA topoisomerase IV and gyrase affinity evaluation supported by molecular docking studies.
Szulczyk D; Dobrowolski MA; Roszkowski P; Bielenica A; Stefańska J; Koliński M; Kmiecik S; Jóźwiak M; Wrzosek M; Olejarz W; Struga M
Eur J Med Chem; 2018 Aug; 156():631-640. PubMed ID: 30031974
[TBL] [Abstract][Full Text] [Related]
17. Novel
Ghorab MM; Alqahtani AS; Soliman AM; Askar AA
Int J Nanomedicine; 2020; 15():3161-3180. PubMed ID: 32440116
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial evaluation and in silico studies of coumarin derivatives tagged with pyrano-pyridine and pyrano-pyrimidine moieties as DNA gyrase inhibitors.
Fayed EA; Nosseir ES; Atef A; El-Kalyoubi SA
Mol Divers; 2022 Feb; 26(1):341-363. PubMed ID: 33895960
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel 2-aminobenzothiazole derivatives as potential antimicrobial agents with dual DNA gyrase/topoisomerase IV inhibition.
Ismail MMF; Abdulwahab HG; Nossier ES; El Menofy NG; Abdelkhalek BA
Bioorg Chem; 2020 Jan; 94():103437. PubMed ID: 31812260
[TBL] [Abstract][Full Text] [Related]
20. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
